Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Apr 13;18(4):e0284411.
doi: 10.1371/journal.pone.0284411. eCollection 2023.

Efficacy and safety of Weifuchun tablet for chronic atrophic gastritis: A systematic review and meta-analysis

Longhua Wang  1 , Xia Ding  2 , Ping Li  1 , Fuwen Zhang  1 , Shuying Ru  1 , Fenglei Wang  1 , Lan Li  3
Affiliations
Meta-Analysis

Efficacy and safety of Weifuchun tablet for chronic atrophic gastritis: A systematic review and meta-analysis

Longhua Wang et al. PLoS One. .

Abstract

Background: Chronic atrophic gastritis is a significant premalignant lesion of gastric carcinoma. There is a great need to prevent the progression to gastric carcinoma through early intervention and treatment for chronic atrophic gastritis. Weifuchun, a famous Chinese patent drug, has been widely used for chronic atrophic gastritis in China. However, it remains unclear whether Weifuchun is effective for atrophic gastritis.

Objective: To determine the effectiveness and safety of Weifuchun for chronic atrophic gastritis.

Methods: We systematically retrieved seven databases (Cochrane Library, EMBASE, PubMed, China National Knowledge Infrastructure, Wanfang database, Chinese Scientific Journals Database, and Chinese Biological Medical Database) from their inception to October 5, 2022. Methodological quality was examined using the Cochrane Risk of bias tool. We also used RevMan 5.4 software for statistical analysis to examine the effectiveness and safety of Weifuchun.

Results: Fifteen studies with 1,488 patients were enrolled in this meta-analysis. The study indicated that Weifuchun was more effective (RR 1.52; 95% CI 1.41, 1.63; p<0.00001) than Western medicine and other Chinese patent medicine. In addition, Weifuchun was more effective in improving gastric mucosal under gastroscopy, improving histopathologic changes of gastric mucosal, and inhibiting Helicobacter pylori. However, no significant difference in safety was examined between Weifuchun and the control group (RR 2.83; 95% CI 0.85, 9.38; P = 0.09).

Conclusions: The meta-analysis revealed a significant statistical difference with Weifuchun in effectiveness compared to the control group. However, there was no significant difference in safety. Thus, more high-quality clinical studies are needed in the future.

Trial registration: Registration number CRD42022365703.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Flow chart of study screening.
Fig 2
Fig 2
(a) Risk of bias summary. (b) Risk of bias graph.
Fig 3
Fig 3. Forest plot of clinical efficacy.
Fig 4
Fig 4. Forest plot of sensitivity analysis of clinical efficacy.
Fig 5
Fig 5. Funnel plot of clinical efficacy.
Fig 6
Fig 6. Funnel plot of clinical efficacy after excluding two studies.
Fig 7
Fig 7. Forest plot of improvement of gastric mucosa under gastroscopy.
Fig 8
Fig 8. Forest plot of improvement of histopathologic variations of the gastric mucosa.
Fig 9
Fig 9. Forest plot of H pylori inhibition rate.
Fig 10
Fig 10. Forest plot of safety evaluation.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al.. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660 . - DOI - PubMed
    1. Kakeji Y, Ishikawa T, Suzuki S, Akazawa K, Irino T, Miyashiro I, et al.. A retrospective 5-year survival analysis of surgically resected gastric cancer cases from the Japanese Gastric Cancer Association nationwide registry (2001–2013). Gastric Cancer. 2022;25(6):1082–1093. doi: 10.1007/s10120-022-01317-6 . - DOI - PubMed
    1. Carneiro F, Machado JC, David L, Reis C, Nogueira AM, Sobrinho-Simões M. Current thoughts on the histopathogenesis of gastric cancer. Eur J Cancer Prev. 2001;10(1):101–2. doi: 10.1097/00008469-200102000-00013 . - DOI - PubMed
    1. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process—First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992;52(24):6735–40. . - PubMed
    1. Kapadia CR. Gastric atrophy, metaplasia, and dysplasia: a clinical perspective. J Clin Gastroenterol. 2003;36(5 Suppl):S29–36; discussion S61-2. doi: 10.1097/00004836-200305001-00006 . - DOI - PubMed

MeSH terms

Grants and funding

The author(s) received no specific funding for this work.
-